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The initial course of daily functioning in multiple sclerosis: a three-year
follow-up study
V de Groot*,1,2, H Beckerman1,2, GJ Lankhorst1,2, CH Polman3 and LM Bouter2
1Department of Rehabilitation Medicine, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The
Netherlands; 2Institute for Research in Extramural Medicine, VU University Medical Center, P.O. Box 7057, 1007 MB
Amsterdam, The Netherlands; 3Department of Neurology, VU University Medical Center, P.O. Box 7057, 1007 MB
Amsterdam, The Netherlands
We studied the initial course of daily functioning in multiple sclerosis (MS). A cohort of 156 recently diagnosed patients was prospectively
followed for three years (five measurements). Domains of interest were neurological deficits, physical functioning, mental health, social
functioning and general health. An a priori distinction was made between a relapse onset group (n/128) and a non-relapse onset group
(n/28). At baseline, neurological deficits are relatively minor for most patients, 26.3% have aberrant physical functioning scores, 38.5%
have aberrant social functioning scores, 9% have aberrant mental health scores and 25% have aberrant general health scores. The
neurological deficits and physical functioning deteriorated significantly over time. This deterioration was more pronounced and clinically
relevant in the non-relapse onset group only. Mental health showed a significant, but not clinically relevant deterioration over time. Social
functioning and general health showed non-significant effects for time. It is concluded that in the initial stage of MS, when neurological
deficits are relatively minor and mental health is relatively unaffected, patients in both groups experience limitations in daily functioning.
Patients in the non-relapse onset group have progressive neurological symptoms that are accompanied by progressive limitations in
physical functioning, but not by progressive limitations in the other domains.
Multiple Sclerosis (2005) 11, 713/718
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Introduction
Most longitudinal studies on the clinical course of multi-
ple sclerosis (MS) in large study populations have only
used the Expanded Disability Status Scale (EDSS) as
outcome measure,17 which is subject to criticism.810 A
clear limitation is that it combines impairments and
disability into one scale. Moreover, the instrument is
heavily biased towards locomotor function, and does not
cover other relevant domains of functioning. Studies that
address other domains of functioning are predominately
cross-sectional,11 thereby not providing insight into the
course of MS in these domains. Although the information
obtained in these studies is certainly of value, long-
itudinal studies of carefully and comprehensively docu-
mented cohorts of patients with MS would improve our
knowledge on the course of MS in relevant domains of
daily functioning.
We studied the initial course of MS in the domains of
neurological deficits, physical functioning, mental health,
social functioning and general health for the relapse onset
group (RO, Relapsing Remitting MS (RRMS) and Second-
ary Progressive MS (SPMS)) and the non-relapse onset
group (NRO, Primary Progressive MS (PPMS) and patients
for whom the type is unknown at six months) in the first
three years.
Methods
All consecutive potentially eligible patients visiting the
outpatient clinics of five participating neurology depart-
ments were invited to participate in the study. A cohort of
156 MS patients, diagnosed less than six months previously
and aged 16/55 years, was recruited and prospectively
followed for three years. Diagnoses were made according to
the Poser-criteria for definite MS.12 Patients with other
neurological disorders, systemic or malignant neoplastic
diseases were excluded. Measurements took place at base-
line, after six months, and after one, two and three years. In
case of a relapse, the measurements were postponed for a
few weeks until the relapse had subsided. Patients were
visited at home in order to minimize drop-out.
The cohort was sub-divided into two a priori defined
groups on the basis of disease type, determined six
months after inclusion in the study.13 The RO group
consisted of patients with RRMS or SPMS, and was the
reference category in the analysis. The NRO group con-
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sisted of patients with PPMS and patients with MS for
which the disease type was unknown at six months.
The EDSS,14 the Functional Independence Measure
(FIM)15 and the Medical Outcome Study Short Form 36
(SF36),16,17 or their sub-scales, were used to assess the
domains of neurological deficits, physical functioning,
mental health, social functioning and general health
(Table 1). The FIM and SF36 scores were transformed to
a scale that ranged from 0 (worst) to 100 (best). The EDSS
was used in its original format, where 0 indicates no
neurological deficits and 10 indicates death due to MS.
The EDSS14 consists of a thorough neurological assess-
ment of the seven neurological systems (visual/optic,
brainstem, pyramidal, cerebellar, bowel/bladder, mental
and other) and provides information about walking ability,
use of walking aids and ability to perform self-care
activities. Lower scores on the EDSS are determined
with a scoring paradigm based on the scores obtained
from the neurological systems, intermediate scores are
predominantly based on walking ability and higher scores
are mainly based on the inability to perform self-care
activities. Reliability has been shown to be moderate.10
Therefore, only experienced raters were involved in the
scoring.
The FIM consists of a motor function (FIMmf, 13 items)
and a cognitive function (FIMcf, five items) sub-scale.15
The items address the activities of daily living and are
scored on the basis of a semi-structured interview. The
validity of the FIM has been established for use in
inpatient and outpatient rehabilitation settings, and its
reliability is good.18,19
The SF3616,17 is a questionnaire that assesses eight
domains (physical functioning (SF36pf), mental health
(SF36mh), bodily pain, vitality, social functioning
(SF36sf), role physical (SF36rp), role emotional (SF36re),
general health perception (SF36gh)). Its validity and
reliability have been extensively studied.16,17 For MS it
is not recommended to calculate physical and mental
component scores because scaling assumptions would be
violated.20
To study the differences in SF36 scores between a healthy
population and the study population, we used reference
data on an age-matched healthy Dutch reference popula-
tion, derived from Aaronson et al .17 The cut-off was set at
1.96 standard deviations below the mean of the reference
population. EDSS scores /0 and FIM scores B/100 were
considered aberrant. We calculated 95% confidence inter-
vals (95% CI) around the proportion of patients with
aberrant scores.
For the longitudinal analysis of the domains of neuro-
logical deficits, physical functioning, mental health and
general health perception, data is presented on six
models, using raw data for the graphs and ‘linear’ general-
ized estimating equations (GEE)21 from the Statistical
Package for Interactive Data Analysis (SPIDA) version
6.05 from the Statistical Computing Laboratory for the
analysis. The correlation structure was chosen on the basis
of the correlation matrix of the outcome measures, and set
at exchangeable (i.e., correlation coefficients between the
first and successive measurements are approximately
equal) for all outcomes except the cognitive sub-scale of
the FIM that was set at four-dependence (i.e., correlation
coefficients between the first and successive measure-
ments are progressively smaller). For the domain of social
functioning (SF36rp, SF36re and SF36sf) data is presented
on three models using raw data for the graphs and
‘binomial’ GEE for the analysis. Because the data showed
strong floor and ceiling effects, we distinguished a group
scoring within the norm and a group with scores deviating
from the norm, using a cut-off of 1.96 standard deviations
below the mean of an age-matched Dutch reference
population.17 Time was modelled as a continuous variable
expressed in years. To test for differences in the course of
both groups we used an interaction term time/group. The
significance level for time, group and time/group was set
at 0.05. Determining the minimally clinically important
difference (MCID) depends on numerous factors and
assumptions.22 For the present study, the MCID was set
at a 10% difference for all outcome measures.
Results
Table 2 shows the baseline characteristics of the patients.
Most characteristics comply with the expected pattern:
64% females, approximately 80% with a relapse onset,
more females than males in the RRMS group, more males
Table 1 Domains of interest, (sub-scales of) outcome measures used and percentage (95% CI) of MS patients with aberrant scores at
baseline
Domain Outcome measures Abbreviation Percentage with aberrant
scores at baseline (%)
Neurological deficits Expanded Disability Status Scale EDSS 96.8 (98.2/95.4)*
Physical functioning Functional Independence Measure motor function FIMmf 74.4 (70.9/87.9)**
SF36 physical functioning SF36pf 26.3 (19.4/33.2)***
Mental health FIM cognitive function FIMcf 64.7 (60.9/68.5)**
SF36 mental health SF36mh 9 (4.5/13.5)***
Social functioning SF36 role physical SF36rp 38.5 (30.8/46.1)***
SF36 role emotional SF36re 12.2 (7/17.3)***
SF36 social functioning SF36sf 12.8 (7.6/18.1)***
General health SF36 general health perception SF36gh 25 (18.2/31.8)***
SF36, Medical Outcome Study Short Form 36; *Percentage scoring ]/1; **Percentage scoring B/100; ***Percentage scoring worse than
1.96 standard deviations below the mean of the reference data obtained from Aaronson et al .17
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than females in the PPMS group, and more severe
neurological deficits in the groups with a progressive
disease course.1,4,6 Seven patients were lost to follow-up
(three after one year, one after two years and three after
three years) and only 1.9% of the measurements were
missing.
Table 1 shows the proportion of patients with aberrant
scores for all outcome measures. Only 3% of the
patients have no neurological symptoms. Although it
seems as if major problems exist on the FIM sub-scales,
only 17.3% of patients score B/90 points on the FIMmf
and 10.2% of patients score B/90 points on the FIMcf.
This indicates that current disabilities are relatively minor
for most patients. Deviations from normal are most
pronounced for the sub-scales SF36pf, SF36rp and
SF36gh.
The course of MS for the two groups can be found
in Figure 1 (raw data) and the corresponding results of
the GEE analysis can be found in Table 3. The neurological
deficits (EDSS) and physical functioning (FIMmf and
SF36pf) deteriorate in the first three years (time is
significant: see Table 3 and Figure 1A, B). For the FIMmf
there is a difference between the two groups that does
not change over time (group is significant: see Table 3),
but for the EDSS and the SF36pf the deterioration is
more pronounced in the NRO group (time/group is
significant: see Table 3). In the NRO group, the change
in EDSS and SF36pf over the first three years exceeds the
MCID (EDSS 1.2 and SF36pf 15 units). In the first three
years mental health, as measured with the FIMcf, shows a
deterioration (3.6 units, statistically significant but smal-
ler than the MCID) that is the same in both groups (time is
significant: see Table 3 and Figure 1C). Mental health, as
measured with the SF36mh, does not change significantly.
For the other scales no change occurs in the first three
years (time is not significant: see Table 3 and Figure 1C, D,
E and F).
Scores for a specific group at a specific point in time can
be calculated using the results from Table 3 in a linear
regression formula. As an example, we will calculate the
EDSS, FIMmf and SFrp of a patient with MS in the NRO




FIMmf 96:11:3time (in years) 6:0group
(RO0; NRO1)
 96:11:326:0187:5
The situation regarding SF36rp is slightly more complex
because the results are presented as an odds ratio (OR).
First, the OR from Table 3 is reverted to the original
logistic coefficient by taking the natural log (ln). This
logistic coefficient is then multiplied by time (in years),
and finally e is raised to the power of this coefficient.
SFrpetime (in years)ln(1:1) etime0:095 e20:095
e0:19 1:2
The number obtained (1.2) is an estimate of the odds (ratio
of the probability that the patient deviates from the norm
to the probability that he does not) that this patient will
have an aberrant social functioning score.
Discussion
At baseline, the domains of physical functioning (SF36pf),
social functioning (SF36rp) and general health (SF36gh)
are markedly affected. Although both groups are affected,
in the domains of physical functioning and general health
the NRO group is more severely affected than the RO
group, whereas in the domain of social functioning there
is no difference between both groups. Surprisingly, mental
health is relatively unaffected. These results show that in
the initial stage of the disease, when the neurological
deficits are relatively minor and mental health is relatively
unaffected, patients in both groups do already experience
limitations in daily functioning.
In the first three years after diagnosis, the course differs
not only between the RO and the NRO group, but also
between the five domains. In the domains of neurological
deficits and physical functioning the NRO group shows
clinically relevant deterioration, whereas the RO groups
stays relatively stable. In the domains of mental health,
social functioning and general health, neither the RO nor
the NRO group show any clinically relevant changes. This
indicates that patients in the NRO group have progressive
neurological symptoms that are accompanied by progres-
Table 2 Baseline characteristics of patients with multiple sclerosis
Relapse onset Non-relapse onset Total
RR SP PP Unknown at six months
n (%) 120 (77) 8 (5) 25 (16) 3 (2) 156 (100)
Age 35.5 (8.9) 48.2 (6.7) 43.2 (8.9) 45.5 (6.9) 37.6 (9.5)
Female (%) 84 (70.0) 3 (37.5) 11 (44) 3 (100) 101 (64)
Time since diagnosis (year) 0.26 (0.15/0.41) 0.33 (0.24/0.48) 0.28 (0.15/0.33) 0.14 (0.14/0.17) 0.26 (0.15/0.40)
Time since symptoms (year) 1.83 (0.67/4.40) 7.50 (3.35/14.51) 2.10 (1.07/3.15) 3.62 (3.53/0.63) 2.15 (0.79/4.36)
Number of exacerbations 2.0 (1.0/3.0) 2.0 (1.0/7.0) 0 (0/0) 0 (0/0) 2.0 (1.0/3.0)
EDSS 2.0 (2.0/3.0) 3.0 (2.5/3.9) 3.0 (2.5/4.0) 2.5 (2.0/4.0) 2.5 (2.0/3.0)
n (percentage), mean (SD) or median (IQR). RR, relapsing remitting multiple sclerosis; SP, secondary progressive multiple sclerosis; PP,
primary progressive multiple sclerosis.
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sive limitations in physical functioning, but not by
progressive limitations in the other domains.
In the later stages of MS, mental health is negatively
affected and there is a relationship between disease
severity and mental health.23 In contrast to what we
expected, we found that mental health was relatively
unaffected at baseline or after three years, for which there
is no good explanation. Even though the majority of the
study population showed only mild neurological symp-
toms at baseline, we expected that the emotional burden
shortly after the diagnosis would have a negative influence
on mental health. However, the interval between making
the diagnosis and inclusion in the study (maximal six
months) may be long enough for patients to recover from
an initial deterioration in mental health. Another explana-
tion might be that the outcome measure that was used was
not sensitive enough to detect problems in this area.
There are some important strengths of this study. The
cohort consists of incident cases of MS, which means that
the start of participation in this cohort is clearly defined.






































































































































Figure 1 Initial course of MS in the domains of neurological deficits, physical functioning, mental health, social functioning and
general health perception. *Graphs are based on raw data. EDSS, Expanded Disability Status Scale; FIMmf, Functional Independence
Measure motor function; SF36pf, Medical Outcome Study Short Form 36 items physical functioning; FIMcf, FIM cognitive function;
SF36mh, SF36 mental health; SF36rp, SF36 role physical; SF36re, SF36 role emotional; SF36sf, SF36 social functioning; SF36gh, SF36
general health perception; RO, relapse onset group; NRO, non-relapse onset group.
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Only seven patients were lost to follow-up. Finally, we
used a powerful design to study daily functioning. To our
knowledge, this is the first longitudinal study that
simultaneously assesses several domains of daily func-
tioning. The longitudinal measurements, the concurrent
use of several outcome measures at the same points in
time, and the use of longitudinal data analysis techniques
enable us to make a detailed and comprehensive descrip-
tion of the course of daily functioning in MS.
A potential weakness is the definition of the type of MS.
RRMS is relatively easy to recognize and accounts for the
majority of the cases. In practice, PPMS is more difficult to
recognize. Furthermore, there is a small sub-group that
cannot be classified in the early stages of the disease.
During follow-up, it is easier to determine the type of MS,
so we chose to dichotomize the patients on the basis of
their disease onset type determined six months after
inclusion in the study.
Another potential problem in this study is that five
patients were classified as SPMS at baseline. This is rather
unexpected in this incidence cohort, because this type of
MS is normally preceded by RRMS. Table 2 shows a long
time since the first symptoms for these patients. Looking
carefully at their history, it became clear that for all of
these patients there was a delay in making the diagnosis,
either caused by the patient or the physician. This delay
might lead to onset confounding,24,25 because time since
first symptoms is related to disease progression and to
conversion of RRMS into SPMS. To study the possibility
of onset confounding, we repeated the analysis and
adjusted for time since first symptoms at baseline (a
logarithmic transformation was applied to obtain a normal
distribution). Because none of the coefficients showed a
considerable change, it is concluded that onset confound-
ing did not play a major role in the present study.
Although this study clearly shows that in the early phase
of MS, functioning is already seriously affected, knowl-
edge about the precise mechanisms underlying this lim-
ited functioning is scarce. Clinicians might be encouraged
to pay special attention to daily functioning in patients
who visit their clinic, and explore the possible causes,
beside neurological deficits, of the problems in daily
functioning. Factors that might contribute to problems in
daily functioning might be patient-related, such as fatigue,
personality, depression, and uncertainty about the future,
or more related to the environment, such as social support
and work related factors. Future studies should focus on
the determinants of this limited functioning in order to
enhance our understanding of these mechanisms and to
provide clinicians with information that can be used in the
development of effective treatments.
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